

South Staffordshire Area Prescribing Group Prescribing Guidance Freestyle Libre[®] Glucose Monitoring System

Freestyle Libre[®] Glucose Monitoring System is expected to be available to prescribe on the NHS from 1st November 2017 subject to local approval.

As a medical device listed in the national Drug Tariff, Freestyle Libre[®] is allowable on NHS prescriptions however the decision on whether the product is funded for prescribing locally is down to individual Clinical Commissioning Groups (CCGs).

FreeStyle Libre[®] has not been demonstrated to be cost-effective and in the absence of a positive technology appraisal (TA), produced and published by the National Institute for Health and Care Excellence (NICE), is not recommended for routine funding in primary care.

Within South Staffordshire Clinical Commissioning Groups, until the full clinical and cost effectiveness of Freestyle Libre[®] is reviewed, the routine prescribing of FreeStyle Libre[®] for all patients with type 1 or type 2 diabetes is **not recommended**.

It is expected that the review of Freestyle Libre[®] will be undertaken by the South Staffordshire Clinical Priority Advisory Group following a request by the diabetes specialists.

Further information on Freestyle Libre[®] is available in the enclosed East of England Priorities Advisory Committee.¹

In summary

- 1. The South Staffordshire CCGs will not support prescribing of Freestyle Libre[®] on the NHS for any patient.**
- 2. Freestyle Libre[®] will not be included within the South Staffordshire Joint Formulary until a full review is undertaken by the Clinical Priority Advisory Group.**
- 3. This recommendation will be reviewed in the light of new evidence to support the cost effective use of FreeStyle Libre[®].**

References:

1. East Of England Priorities Advisory Committee guidance statement - FreeStyle Libre[®] Glucose Monitoring System. September 2017.